reviewed april 2026|next review october 2026|88 physicians psi has verified|3745 published studies
Kisspeptin
Kisspeptin is a naturally occurring (the body's own) neuropeptide that controls the reproductive hormone cascade by activating GnRH neurons, with loss-of-function mutations causing failure to enter puberty, and early IVF data suggesting a safer alternative to hCG for oocyte maturation triggering.
Evidence landscape: 3745 published studies
3,745 published items. 11 human studies and 145 animal studies. Fundamental reproductive endocrinology with a translational pathway through IVF.
- 11 Human
- 145 Animal
- 44 Reviews
- 3545 Other research
Master switch for the reproductive axis. Loss-of-function mutations in GPR54 cause failure to enter puberty, proving the peptide is essential for reproductive function.
Multiple human studies confirm dose-dependent LH and FSH responses. Early IVF data suggests lower ovarian hyperstimulation risk than hCG triggering.
Not FDA-approved. Was placed on an FDA list that prevents licensed pharmacies from preparing it - expected to be restored to the permitted list.
PSI Assessment
Loss-of-function mutations in a single receptor cause complete failure to enter puberty - that is how essential kisspeptin is to the reproductive hormone cascade. It is the master switch that activates GnRH neurons, which activate LH and FSH, which drive testosterone, estrogen, and fertility. Multiple human studies confirm dose-dependent hormone responses. Early IVF data suggests kisspeptin may trigger oocyte maturation with lower risk of ovarian hyperstimulation. The open question is whether kisspeptin-based therapies will reach FDA approval or remain investigational tools.
The master switch of the reproductive hormone cascade. Loss-of-function mutations cause failure to enter puberty. Early IVF data suggests lower ovarian hyperstimulation risk than hCG.
The mechanism is GPR54 (KISS1R) receptor activation on GnRH neurons in the hypothalamus. Kisspeptin integrates metabolic status, circadian rhythm, and stress signals into the decision of whether to activate the reproductive axis. A single kisspeptin injection triggers a dose-dependent LH pulse in humans. The very short half-life (measured in minutes) limits sustained therapeutic applications but may be advantageous in IVF where a brief, controlled gonadotropin surge is desired.
What the evidence supports
Kisspeptin is the master regulator of the reproductive hormone cascade. Loss-of-function mutations in the GPR54 receptor cause hypogonadotropic hypogonadism with failure to enter puberty. Human studies confirm dose-dependent LH and FSH responses to kisspeptin administration. Early IVF data suggests kisspeptin may trigger oocyte maturation with lower risk of ovarian hyperstimulation syndrome (OHSS) compared to hCG.
What is not yet established
Whether kisspeptin-based IVF protocols are superior to established hCG triggering in controlled comparison trials. The short half-life limits sustained therapeutic applications. Whether kisspeptin has a role in male fertility or hypogonadism management beyond diagnostic use. Optimal dosing and formulation for clinical applications.
Research Evidence
The findings below cover the genetic validation, human gonadotropin response data, and the IVF oocyte maturation application.
Evidence by condition
Evidence dimensions across kisspeptin's investigated applications. Reproductive biology has the deepest evidence. IVF applications have early clinical data.
| Condition | Mechanism | Animal evidence | Human evidence | Replication |
|---|---|---|---|---|
| Reproductive Hormone Disorders | ||||
| Puberty/Development | ||||
| IVF/Fertility | ||||
| Sexual Behavior |
Loss-of-function mutations in GPR54 (KISS1R) cause hypogonadotropic hypogonadism with failure to enter puberty. Gain-of-function mutations cause precocious puberty. This genetic evidence proves kisspeptin is essential for reproductive axis activation.
Genetic validation is the strongest form of biological proof. It establishes that kisspeptin is not merely associated with reproduction - it is required for it.
Human studies confirm dose-dependent LH and FSH responses to kisspeptin administration via both IV and subcutaneous routes. A single injection triggers a measurable LH pulse.
The human pharmacology is well-characterized. Multiple independent groups have confirmed the dose-response relationship.
A randomized trial showed kisspeptin-54 triggered oocyte maturation with significantly lower risk of ovarian hyperstimulation syndrome (OHSS) compared to hCG trigger in IVF protocols.
OHSS is a serious complication of IVF. A safer trigger that avoids OHSS while achieving comparable oocyte maturation would be clinically significant.
11 Human|145 Animal|44 Reviews
View all 3745 indexed studiesHow Kisspeptin Works
Kisspeptin is a family of neuropeptides encoded by the KISS1 (kisspeptin-1) gene. It is the primary upstream regulator of GnRH neurons in the hypothalamus, controlling puberty onset, fertility, and reproductive endocrine function.
Think of kisspeptin as the ignition key for your reproductive system. It activates a chain reaction: kisspeptin tells GnRH neurons to fire, GnRH tells the pituitary to release LH and FSH, and those hormones tell the gonads to produce testosterone or estrogen. Without kisspeptin, the whole system stays off.
For a more detailed view of the biology, here is what researchers have observed at the molecular level.
Kisspeptin binds to the GPR54 (KISS1R) receptor on GnRH neurons in the hypothalamus, triggering GnRH pulse generation. This cascade stimulates LH and FSH release from the pituitary, driving gonadal steroid production. Kisspeptin neurons integrate metabolic, photoperiodic, and stress signals into the decision of whether to activate the reproductive axis. The very short half-life (minutes) reflects rapid enzymatic degradation.
What is Kisspeptin being studied for?
Researchers are studying Kisspeptin across several health conditions. Each condition below is labeled with the strength of evidence that exists for that specific use, not for Kisspeptin overall. This means a compound can have human studies for one condition but only animal data for another.
Reproductive Hormone Disorders
·Human TrialsHuman studies show kisspeptin reliably stimulates LH and FSH release. It has been studied as a diagnostic tool and potential treatment for hypogonadotropic hypogonadism.
Limitations: Optimal formulation, route, and dosing for sustained therapeutic use are not established. Most studies are single-dose or short-duration.
Puberty/Development
·Human TrialsKisspeptin is the primary regulator of puberty onset. Mutations in KISS1R cause failure to enter puberty (loss-of-function) or precocious puberty (gain-of-function).
Limitations: Therapeutic applications for puberty disorders are investigational.
IVF/Fertility
·Animal StudiesEarly clinical data suggests kisspeptin may be a safer alternative to hCG for triggering oocyte maturation in IVF, with lower risk of ovarian hyperstimulation syndrome.
Limitations: Limited to small studies. Not yet adopted in standard IVF protocols. Whether pregnancy rates are comparable to hCG triggering requires larger trials.
Sexual Behavior
·Animal StudiesBrain imaging studies show kisspeptin enhances neural responses to sexual and romantic stimuli, suggesting a role beyond just hormone release.
Limitations: Behavioral effects are preliminary. Clinical applications for sexual dysfunction are not established.
Safety and Regulatory Status
FDA Status: Not FDA-approved for any indication. Under clinical investigation for reproductive medicine applications.
Regulatory status: Was placed on an FDA list that prevents licensed pharmacies from preparing it. Expected to be restored to the permitted list following the February 2026 HHS announcement.
Safety context: Kisspeptin is a naturally occurring (the body's own) neuropeptide. Well tolerated in clinical studies with no significant adverse effects. Most common side effects are mild flushing and abdominal discomfort.
Well tolerated in clinical studies with no significant adverse effects reported. The most common side effects are mild flushing and abdominal discomfort.
Peptide Structure
Technical molecular data for researchers and clinicians.
Questions and Comparisons
Questions the evidence raises for a Kisspeptin discussion.
Comparison and Related Research
Kisspeptin is most often compared with other compounds that modulate reproductive hormone signaling.
Head-to-head comparisons
Full research comparisons covering Kisspeptin and another peptide side by side.
Kisspeptin vs PT-141 (Bremelanotide)
Kisspeptin triggers GnRH release for reproductive function. PT-141 activates melanocortin receptors for sexual desire. Evidence-graded comparison.
View full comparisonRelated compounds
Frequently Asked Questions
References
Each citation links to the original study on PubMed, the U.S. National Library of Medicine database.
- 1.A foundational genetics study that identified loss-of-function mutations in the GPR54 receptor (now called KISS1R) in patients with isolated hypogonadotropic hypogonadism. By demonstrating that disrupted kisspeptin signaling leads to failure of puberty and reproductive function in humans, this paper established kisspeptin as a critical gatekeeper of the reproductive hormone axis.de Roux N et al., 2003 in Proc Natl Acad Sci U S A. View on PubMed
- 2.The first study to demonstrate that intravenous kisspeptin-54 administration potently stimulates LH and FSH release in healthy men. A single bolus injection produced a rapid and significant rise in gonadotropin levels, confirming that the kisspeptin signaling pathway is functional and pharmacologically targetable in adult humans.Dhillo WS et al., 2005 in J Clin Endocrinol Metab. View on PubMed
- 3.A clinical study demonstrating that kisspeptin-54 can safely trigger oocyte maturation in women undergoing IVF who are at high risk of ovarian hyperstimulation syndrome. Unlike the standard hCG trigger, kisspeptin produced a more physiological LH surge and resulted in zero cases of clinically significant OHSS, while still achieving successful oocyte retrieval and pregnancy.Abbara A et al., 2015 in J Clin Endocrinol Metab. View on PubMed
- 4.Published alongside the de Roux study, this New England Journal of Medicine paper identified GPR54 mutations in a large consanguineous family with idiopathic hypogonadotropic hypogonadism. The study confirmed that functional kisspeptin receptor signaling is essential for the onset of puberty and normal reproductive function, and that the defect is specific to the GnRH axis rather than the pituitary or gonads.Seminara SB et al., 2003 in N Engl J Med. View on PubMed
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.